Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Presented positive interim Phase 1 clinical trial data for PSMA-targeting HPN424 in prostate cancer at ASCO20, supporting increased dose escalation Dosed first patient with HPN217 targeting BCMA for the treatment of multiple myeloma, triggering a $50 …